

Supplemental Digital Content 1.doc

Selected Records

- Agarwal SK, Vallurupalli S, Uretsky BF, Hakeem A. Effectiveness of colchicine for the prevention of recurrent pericarditis and post-pericardiotomy syndrome: an updated meta-analysis of randomized clinical data. *Eur Heart J Cardiovasc Pharmacother*. 2015;1:117–125.
- Alabed S, Cabello JB, Irving GJ, et al. Colchicine for pericarditis. *Cochrane Database of Systematic Reviews* [Internet]. 2014 [cited 2020 Aug 11]; Available from: <http://doi.wiley.com/10.1002/14651858.CD010652.pub2>
- Alraies MC, AlJaroudi W, Yarmohammadi H, et al. Usefulness of cardiac magnetic resonance–guided management in patients with recurrent pericarditis. *Am J Cardiol*. 2015;115:542–547.
- Antonatou K, Vasileiou P, Koutsianas C, et al. FRI0496 Long term safety and efficacy of anakinra in adult patients with refractory recurrent idiopathic pericarditis. *Ann Rheum Dis*. 2016;75:618.
- Arguero V, Sanchez A. Management and treatment of acute pericarditis in the emergency room [Internet]. 2018 [cited 2019 Oct 1]. Available from: <https://esc365.escardio.org/Congress/Acute-Cardiovascular-Care-2018/Poster-Session-5-Pulmonary-embolism-Arrhythmias-and-Sudden-Cardiac-Death-Im/168321-management-and-treatment-of-acute-pericarditis-in-the-emergency-room#abstract>
- Artom G, Koren-Morag N, Spodick DH, et al. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. *Eur Heart J*. 2005;26:723–727.
- Baskar S, Betancor J, Patel K, et al. Cardiac MRI in evaluation and management of pediatric pericarditis. *Prog Pediatr Cardiol*. 2018;50:39–45.
- Brown A, Liu X, Chatterjee S. Azathioprine may be an effective steroid sparing agent in patients with isolated recurrent pericarditis - ACR Meeting Abstracts [Internet]. 2015 [cited 2019 Dec 23]. Available from: <https://acrabstracts.org/abstract/azathioprine-may-be-an-effective-steroid-sparing-agent-in-patients-with-isolated-recurrent-pericarditis/>
- Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: The AIRTRIP randomized clinical trial. *JAMA*. 2016;316:1906–1912.
- Brucato A, Brambilla G, Adler Y, et al. Therapy for recurrent acute pericarditis: a rheumatological solution? - PubMed - NCBI. *Clin Exp Rheumatol*. 2006;24:45–50.
- Brucato A, Brambilla G, Moreo A, et al. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. *Am J Cardiol*. 2006;98:267–271.
- Costain N, Choi S, Vaillancourt C. LO099: Colchicine in acute and recurrent pericarditis: a meta-analysis. *Can J Emergency Med*. 2016;18:S64–S64.

- Crotty C, Forsythe A, Magestro M. PCV9 Unmet needs & burden of recurrent pericarditis (RP): results of a systematic literature review (SLR). *Value in Health*. 2019;22:S119.
- Eun J, Smith A. Safety and efficacy of colchicine therapy in the prevention of recurrent pericarditis. *Am J Health Syst Pharm*. 2014;71:1277–1281.
- Finetti M, Insalaco A, Cantarini L, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. *J Pediatr*. 2014;164:1425-1431.e1.
- Furqan M, Abdullah R, Verma B, et al. Effect of anakinra on colchicine resistant and steroid dependent recurrent pericarditis: a systemic review and meta-analysis. *J Am Coll Cardiol*. 2019;73:1017.
- Imazio M, Lazaros G, Maestroni S, et al. Anakinra for recurrent pericarditis: results from a real world European registry [Internet]. 2018 [cited 2019 Dec 23]. Available from: <https://esc365.escardio.org/Congress/ESC-Congress-2018/Best-Posters-6-Best-Posters-in-pericardial-disease/176302-anakinra-for-recurrent-pericarditis-results-from-a-real-world-european-registry-beat-registry>
- Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COLchicine for REcurrent pericarditis) trial. *Arch Internal Med*. 2005;165:1987–1991.
- Imazio M, Lazaros G, Picardi E, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. *J Cardiovasc Med*. 2016;17: 263-269.
- Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis. *Circulation*. 2005;112:2012–2016.
- Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. *N Engl J Med*. 2013;369:1522–1528.
- Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. *Lancet*. 2014;383:2232–2237.
- Imazio M, Brucato A, Pluymaekers N, et al. Recurrent pericarditis in children and adolescents: a multicentre cohort study. *J Cardiovasc Med*. 2016;17:707-712.
- Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis. *Circulation*. 2008;118:667–671.
- Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. *Ann Internal Med*. 2011;155:409–414.
- Imazio M, Brucato A, Forno D, et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. *Heart*. 2012;98:1078–1082.
- Imazio M, Brucato A, Adler Y, et al. Prognosis of idiopathic recurrent pericarditis as determined from previously published reports. *Am J Cardiol*. 2007;100:1026–1028.

- Imazio M, Demichelis B, Parrini I, et al. Management, risk factors, and outcomes in recurrent pericarditis. *Am J Cardiol*. 2005;96:736–739.
- Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis: A management program for outpatient therapy. *J Am Coll Cardiol*. 2004;43:1042–1046.
- Jain S, Thongprayoon C, Espinosa RE, et al. Effectiveness and safety of anakinra for management of refractory pericarditis. *Am J Cardiol*. 2015;116:1277–1279.
- Klein A, Cremer P, Kontzias A, et al. Recurrent pericarditis epidemiology in the United States (2013-2018). In: American College of Epidemiology. Pasadena, CA: 2019.
- Kumar N, Pandey A, Jain P, Garg N. Acute pericarditis-associated hospitalization in the USA: a nationwide analysis, 2003-2012. *Cardiology*. 2016;135:27–35.
- Kumar A, Sato K, Verma B, et al. P6296 Quantitative assessment of pericardial delayed hyperenhancement: have we finally found an objective criteria to diagnose and treat recurrence? *Eur Heart J*. 2017; 38; ehx493.P6296.
- Kuo I fan, Pearson GJ, Koshman SL. Colchicine for the primary and secondary prevention of pericarditis: an update. *Ann Pharmacother*. 2009;43:2075–2081.
- Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. *Circulation*. 2014;130:1601–1606.
- Lattuca B, Khoueiry Z, Leclercq F, et al. 090: Could heart rate predict duration of hospitalizations for patients admitted for acute pericarditis? *Arch Cardiovasc Dis Suppl*. 2013;5:29.
- Lazaros G, Imazio M, Brucato A, et al. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence. *J Cardiovasc Med (Hagerstown)*. 2016;17:256–262.
- Lazaros G, Antonopoulos A, Karavidas A, et al. P6301 Factors predicting non-steroidal drugs failure and switch to corticosteroid treatment in patients with acute pericarditis. *Eur Heart J* [Internet]. 2017;38; ehx493.P6301
- Lazaros G. The role of admission C-reactive protein in predicting recurrences in treatment naive patients with a first episode of acute pericarditis [Internet]. Italy: 2016 [cited 2020 Aug 11]. Available from: <https://esc365.escardio.org/Congress/ESC-CONGRESS-2016/Poster-session-7-Cardiomyopathy/140473-the-role-of-admission-c-reactive-protein-in-predicting-recurrences-in-treatment-naive-patients-with-a-first-episode-of-acute-pericarditis>
- Lazaros G, Vasileiou P, Koutsianas C, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. *Ann Rheum Dis*. 2014;73:2215–2217.
- Li Y-L, Qiao S-B, Wang J-Y, et al. Colchicine in addition to conventional therapy for pericarditis recurrence : An update meta-analysis. *Herz*. 2016;41:630–638.

- Lotrionte M, Biondi-Zoccai G, Imazio M, et al. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. *Am Heart J*. 2010;160:662–670.
- Lutschinger LL, Rigopoulos AG, Schlattmann P, et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. *BMC Cardiovasc Disord*. 2019;19:207.
- Mendel A, Mardigyan V. Anakinra for treatment of severe idiopathic pericarditis: Experience in a series of seven patients. *J Rheumatol*. 2017;44: 854.
- Mody P, Bikdeli B, Wang Y, et al. Trends in acute pericarditis hospitalizations and outcomes among the elderly in the USA, 1999-2012. *Eur Heart J Qual Care Clin Outcomes*. 2018;4:98–105.
- Moretti M, Buiatti A, Merlo M, et al. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis. *Am J Cardiol*. 2013;112:1493–1498.
- Norrid SE, Oliphant CS. Colchicine for the treatment of acute and recurrent pericarditis. *Ann Pharmacother*. 2014;48:1050–1054.
- Ratnapalan S, Brown K, Benson L. Children presenting with acute pericarditis to the emergency department. *Pediatr Emerg Care*. 2011;27: 581-585.
- Raval J, Nagaraja V, Eslick GD, Denniss AR. The role of colchicine in pericarditis--a systematic review and meta-analysis of randomised trials. *Heart Lung Circ*. 2015;24:660–666.
- Sato K, Kumar A, Verma B, et al. Initiation of disease-modifying antirheumatic drugs and biological agents leads to early resolution of pericardial delayed hyperenhancement in patients with recurrent pericarditis. *J Am Coll Cardiol*. 2018;71:A1486.
- Schenone AL, Menon V. Colchicine in pericardial disease: from the underlying biology and clinical benefits to the drug-drug interactions in cardiovascular medicine. *Curr Cardiol Rep*. 2018;20:62.
- Schwieb NC, Hale GM, Davies ML. Treatment of adults with idiopathic recurrent pericarditis: novel use of immunotherapy. *Pharmacotherapy: J Human Pharmacol & Drug Ther*. 2017;37:305–318.
- Shakti D, Hehn R, Gauvreau K, et al. Idiopathic pericarditis and pericardial effusion in children: contemporary epidemiology and management. *JAHA*. 3:e001483.
- Sigvardt FL, Hansen ML, Kristensen SL, et al. 5036: Increased 1-year mortality among patients discharged following hospitalization for pericarditis - a nationwide cohort study. *Eur Heart J*. 2019;40: ehz746.0039.
- Siniorakis E, Spyridon Arvanitakis S, Pantelis N. The role of restricted physical activity in the prevention of recurrent idiopathic pericarditis. [Internet]. In: *Eur J Prev Cardiol*. Dublin: SAGE Publications UK: London, England; 2012 [cited 2020 Aug 11]. Available from: <https://journals.sagepub.com/doi/10.1177/2047487312448015>
- Søgaard KK, Sørensen HT, Smeeth L, Bhaskaran K. Acute pericarditis and cancer risk: a matched cohort study using linked UK primary and secondary care data. *JAHA*. 2018;7:e009428.

Sud K, Sabharwal B, Wei X, Herzog E. In-hospital outcomes and etiologies for 30-day readmissions in patients with acute pericarditis. *J Am Coll Cardiol*. 2018;71:A786.

Vassilopoulos D, Vasileiou P, Koutsianas C, Antonatou K. Anakinra for the management of resistant idiopathic recurrent pericarditis in adults - ACR Meeting Abstracts [Internet]. 2014 [cited 2019 Dec 23]. Available from: <https://acrabstracts.org/abstract/anakinra-for-the-management-of-resistant-idiopathic-recurrent-pericarditis-in-adults/>

Verma B, Sato K. Pericardial effusion: A reliable imaging indicator of underlying inflammation in recurrent pericarditis. *J Am Soc Echocardiogr*. 2018;31:B85.

Verma BR, Ala C, Sato K, et al. Higher quantitative pericardial delayed hyperenhancement in patients with recurrent pericarditis after a year of medical therapy is associated with frequent relapses. *J Am Coll Cardiol*. 2018;71:A1644.